Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 29.1% in the 4th quarter, Holdings Channel reports. The fund owned 31,052 shares of the medical instruments supplier’s stock after selling 12,760 shares during the period. Jacobs & Co. CA’s holdings in Becton, Dickinson and Company were worth $7,044,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BDX. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth approximately $33,000. Tompkins Financial Corp grew its position in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares in the last quarter. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Abound Wealth Management grew its position in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,747 shares of company stock valued at $1,949,520. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $0.59 during midday trading on Friday, hitting $235.02. The company’s stock had a trading volume of 1,590,186 shares, compared to its average volume of 1,723,689. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock’s 50-day moving average price is $226.94 and its 200-day moving average price is $232.47. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $248.42. The company has a market capitalization of $68.16 billion, a PE ratio of 39.57, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the business earned $3.42 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were paid a $1.04 dividend. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.77%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BDX. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.